Patents Examined by Melissa J Perreira
  • Patent number: 11787764
    Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: October 17, 2023
    Assignees: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Martin John Schnermann, Peter C. W. Kim, Jaepyeong Cha, Roger Rauhauser Nani
  • Patent number: 11779663
    Abstract: The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: October 10, 2023
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventors: Robert Yongxin Zhao, Qingliang Yang, Yuanyuan Huang, Shun Gai, Linyao Zhao, Hangbo Ye, Huihui Guo, Qianqian Tong, Minjun Cao, Junxiang Jia, Chengyu Yang, Wenjun Li, Xiaomai Zhou, Hongsheng Xie, Chen Lin, Zhixiang Guo, Zhicang Ye
  • Patent number: 11766483
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 26, 2023
    Assignee: CENTAURI THERAPEUTICS LIMITED (GB/GB)
    Inventors: Michael Westby, Melanie Glossop, Christine Watson, Christopher Pickford
  • Patent number: 11738100
    Abstract: Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: August 29, 2023
    Assignee: CLARITY PHARMACEUTICALS LIMITED
    Inventors: Matthew John Harris, Sean Lumb
  • Patent number: 11696686
    Abstract: The invention is directed to methods for diagnosing reperfusion/non-reperfusion hemorrhage and predicting cardiac arrhythmias and sudden cardiac death in subjects comprising using imaging techniques to detect regional iron oxide deposition. The invention also provides treatment methods for subject at increased risk of sudden cardiac death.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 11, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Rohan Dharmakumar, Ivan Cokic
  • Patent number: 11690524
    Abstract: The invention provides various methods of identifying myocardial infarction (MI) patients who have microvascular obstruction (MO), persistent microvascular obstruction (PMO), reperfusion hemorrhage, iron deposition, chronic iron deposition, and/or fat infiltration/accumulation. The invention provides various methods of identifying myocardial infarction (MI) patients who are at risk of prolonged inflammation burden in heart, adverse cardiac remodeling, electrical abnormality, mechanical abnormality, malignant cardiac arrhythmia, ischemic heart failure, and/or sudden cardiac death. The invention also provides various methods of treating these MI patients with chelation drugs, anti-inflammatory drugs, fat-lowering drugs, cooling therapies, or device therapies, or their combinations.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Rohan Dharmakumar, Ivan Cokic
  • Patent number: 11661402
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: May 30, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Patent number: 11654205
    Abstract: Generation of bubbles is disclosed to occur within a flow of an aqueous fluid. The bubbles may be formed within a tube of a selected diameter and the bubbles are controlled to exit the tube at a selected diameter. Generally, bubbles are formed to include a diameter of less than 1 millimeter, including less than about 20 microns.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 23, 2023
    Assignee: Oakwood Healthcare, Inc.
    Inventor: James Richard Spears
  • Patent number: 11655236
    Abstract: Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: May 23, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Matthew S. Bogyo, Martijn Verdoes
  • Patent number: 11653984
    Abstract: Multi-angle radiographic imaging enables 3D visualization of internal surgical targets like solid-tumors, heart vessels, blocked glands or any bodily cavities like fallopian or Eustachian tubes for diagnostics and surgery planning. Those images are dimensionally precise and easily replicated as life-forms with 3D printing for exact modeling. The “negative” aspects of the images are the diseased tissues requiring excision, as in a solid-tumor example. Needle biopsies are routine and can be radiographically guided. Similarly, guided needle delivery of a magnetic surgical fluid containing fullerenes into a target site, such as a solid tumor is less invasive than laparoscopic techniques. Introducing an external magnetic field force can then be used to propel, rotate and maneuver fullerenes into cellular matter or into tissue.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: May 23, 2023
    Inventors: Terry Earl Brady, Anthony Lee Dellinger, Lowell Hughes, Melinda K. M. Goddard
  • Patent number: 11638765
    Abstract: The present invention relates to a compound of a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x1 is a spacer or a chemical single bond covalently connecting (A) to the rest of the molecule; x2 is a spacer or a chemical single bond covalently connecting (C) to the rest of the molecule. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 2, 2023
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls -Uni versitaet Heidelberg
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn, Ann-Christin Eder, Jens Cardinale, Martina Benesova
  • Patent number: 11607462
    Abstract: Provided herein are compositions, systems, and methods for minimally-invasive assessment of toxicity-induced tissue injury. In particular, external (e.g., whole-body) scanning is employed to detect toxicity-induced injuries, such as those caused by chemotherapeutics.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: March 21, 2023
    Assignee: Northwestern University
    Inventors: Ming Zhao, Steven E. Johnson
  • Patent number: 11602570
    Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: March 14, 2023
    Assignee: MediBeacon Inc.
    Inventors: Martin P. Debreczeny, Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers
  • Patent number: 11590244
    Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: February 28, 2023
    Assignee: MediBeacon Inc.
    Inventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann, Thomas E. Rogers, Martin P. Debreczeny
  • Patent number: 11578040
    Abstract: The present invention provides the methods of synthesis of [5]helicene compounds and the use of the said compounds conjugating with biomolecules to work as molecular reporter for diagnostic. The compounds in the present invention have the chemical structure illustrated in the formula (1): wherein G is a connecting group composes of 2 carbon atoms selected from the group consisting of ethane and ethylene; A is a separated or connected group selected from the group consisting of cyano and imide; D1 is selected from the group consisting of oxyalkanoic acid, oxyalkanal and oxyalkanesulfonate; and D2 has structure selected from the group consisting of hydroxyl, oxyalkanoic acid, oxyalkanal, alkyl oxyalkanoate, oxyalkanol and oxyalkanesulfonate. The compounds in the present invention compose of aromatic [5]helicene core comprising long it-conjugating system.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 14, 2023
    Assignee: National Science and Technology Development Agency
    Inventors: Thanasat Sooksimuang, Nitsara Karoonuthaisiri, Ratthaphol Charlermroj, Somboon Sahasithiwat, Waraporn Panchan, Manlika Makornwattana, Sudtida Phuengwas, Laongdao Kangkaew
  • Patent number: 11565003
    Abstract: Embodiments of the present disclosure pertain to methods of opening a lipid bilayer by associating the lipid bilayer with a molecule that includes a moving component capable of moving (e.g., rotating) in response to an external stimulus; and exposing the molecule to an external stimulus before, during or after associating the molecule with the lipid bilayer. The exposing causes the moving component of the molecule to move and thereby open the lipid bilayer (e.g., by pore formation). The external stimuli may include an energy source, such as ultraviolet light. The opened lipid bilayer may be a component of cell membranes in vitro or in vivo. The opening of the lipid bilayer may allow for the passage of various materials (e.g., active agents, such as peptide-based drugs) through the lipid bilayer and into cells. Additional embodiments of the present disclosure pertain to the aforementioned molecules for opening lipid bilayers.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 31, 2023
    Assignees: William Marsh Rice University, Durham University
    Inventors: James M. Tour, Robert Pal, Victor García López, Lizanne Nilewski
  • Patent number: 11554184
    Abstract: Compositions and methods for the personalized and targeted therapeutic treatment of diseases and disorders, including the treatment of pain, inflammation, and infectious diseases in a subject. In particular, labeled synthetic cannabinoid therapeutic compositions are provided that include a conjugate of a synthetic cannabinoid compound, a chelator, and a label, that when coupled with imaging may be used to determine in real time optimal dosing and targeting of particular pathways and tissues to provide personalized therapies. Combination therapies are also provided that include one or more synthetic cannabinoid compound and at least one active pharmaceutical ingredient.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: January 17, 2023
    Assignee: Vyripharm Enterprises, Inc.
    Inventor: Jerry L. Bryant, Jr.
  • Patent number: 11554182
    Abstract: The present technology provides compounds as well as compositions including such compounds useful for the treatment of cancers where the compounds are represented by the following formula (I) or a pharmaceutically acceptable salt thereof, wherein M is an alpha-emitting radionuclide.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: January 17, 2023
    Assignee: Cornell University
    Inventors: Justin Wilson, Nikki Thiele
  • Patent number: 11555821
    Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to the active site of carbonic anhydrase, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid, amide, ureido, or polyethylene glycol derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: January 17, 2023
    Assignee: ON TARGET LABORATORIES, INC.
    Inventors: Sumith A. Kularatne, Mini Thomas
  • Patent number: 11549017
    Abstract: This disclosure provides a family of compounds that absorb and fluoresce in the short wave infrared region (SWIR, optionally 1000 nm to 1300 nm), including hydrophilic compounds that exhibit absorption and emission spectral profiles in aqueous solutions substantially similar to those observed in organic solvents such as methanol or DMSO. The compounds can be chemically linked to biomolecules including proteins, nucleic acids, and therapeutic small molecules. The compounds are useful for imaging in a variety of medical, biological and diagnostic applications, including SWIR in vivo imaging of regions of interest within a mammal.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 10, 2023
    Assignee: PerkinElmer Health Sciences, Inc.
    Inventors: Nara Narayanan, Kevin Groves, Guojie Ho